锕锕锕锕锕锕～再深点+在线观看,痛痛痛痛痛痛疼疼色板推特,天天碰天天爱天天摸,成人18毛片女人

您好，歡迎來(lái)到上海士研管理咨詢(xún)有限公司
產(chǎn)業(yè)峰會(huì) 演講局 專(zhuān)家智庫(kù)服務(wù) 峰會(huì)活動(dòng)服務(wù) 整合營(yíng)銷(xiāo)服務(wù)
  • 產(chǎn)業(yè)峰會(huì)：
    以專(zhuān)業(yè)團(tuán)隊(duì)對(duì)產(chǎn)業(yè)和市場(chǎng)客觀(guān)詳實(shí)地調(diào)研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領(lǐng)導(dǎo)者關(guān)注的熱點(diǎn)話(huà)題與領(lǐng)袖代表，為您提供“一站式”的對(duì)話(huà)、分享、社交平臺(tái)!
  • 演講局：
    致力于為全球企業(yè)和機(jī)構(gòu)提供主題演講家、高管大師班、董事會(huì)顧問(wèn)，每項(xiàng)服務(wù)都提供了一種更深入、更具互動(dòng)性的體驗(yàn)，尤其是針對(duì)較小的精選受眾和關(guān)鍵個(gè)人。我們擁有最具影響力的商業(yè)領(lǐng)袖和頂級(jí)專(zhuān)家的資源，他們是各自領(lǐng)域的最杰出的代表。我們的團(tuán)隊(duì)由經(jīng)驗(yàn)豐富的演講和活動(dòng)經(jīng)理組成，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 專(zhuān)家智庫(kù)服務(wù)：
    中國(guó)領(lǐng)先的行業(yè)專(zhuān)家知識(shí)信息服務(wù)供應(yīng)商，為需要專(zhuān)業(yè)洞見(jiàn)的商業(yè)決策者匹配具有一手經(jīng)驗(yàn)的行業(yè)專(zhuān)家，助力他們以更加明確的目標(biāo)和堅(jiān)定的信心做出決策。我們有60萬(wàn)余名專(zhuān)家顧問(wèn)遍布二十多個(gè)行業(yè)，而且每天還在增加！
  • 峰會(huì)活動(dòng)服務(wù)：
    致力于成為全球最專(zhuān)業(yè)的產(chǎn)業(yè)峰會(huì)活動(dòng)提供商，為企業(yè)和機(jī)構(gòu)的產(chǎn)業(yè)性峰會(huì)活動(dòng)提供一站式專(zhuān)業(yè)服務(wù)，包括調(diào)研策劃、定制邀請(qǐng)、營(yíng)銷(xiāo)推廣、運(yùn)營(yíng)組織、項(xiàng)目管理、直播與數(shù)字化會(huì)議等，每項(xiàng)服務(wù)都由經(jīng)驗(yàn)豐富的專(zhuān)業(yè)團(tuán)隊(duì)匹配長(zhǎng)期沉淀的產(chǎn)業(yè)資源予以卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 整合營(yíng)銷(xiāo)服務(wù)：
    致力于成為全球領(lǐng)先的2B營(yíng)銷(xiāo)服務(wù)機(jī)構(gòu)，聚焦產(chǎn)業(yè)高端活動(dòng)、內(nèi)容、渠道的建設(shè)與沉淀，為客戶(hù)提供一站式整合營(yíng)銷(xiāo)解決方案，助力企業(yè)線(xiàn)上線(xiàn)下獲客與品牌筑造。我們深信專(zhuān)業(yè)團(tuán)隊(duì)匹配產(chǎn)業(yè)資源帶來(lái)卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
嘉賓信息
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 首席執(zhí)行官
所屬公司： 邦耀生物
個(gè)人簡(jiǎn)介：
鄭彪博士畢業(yè)于浙江大學(xué)醫(yī)學(xué)院醫(yī)學(xué)系；獲上海復(fù)旦大學(xué)醫(yī)學(xué)院免疫學(xué)碩士及倫敦大學(xué) (King’s College, University of London) 免疫學(xué)博士學(xué)位。曾在美國(guó)馬里蘭大學(xué)醫(yī)學(xué)院 (University of Maryland School of Medicine) 及杜克大學(xué)醫(yī)學(xué)中心 (Duke University Medical Center) 任教。隨后任職于美國(guó)貝勒醫(yī)學(xué)院 (Baylor College of Medicine), 為該校病理和免疫系終身教授。在葛蘭索史克 (GlaxoSmithKline) 研發(fā)中心負(fù)責(zé)免疫學(xué)研究工作。曾任美國(guó)強(qiáng)生公司(Janssen Pharmaceuticals, Johnson & Johnson) 全球副總裁, 負(fù)責(zé)亞太地區(qū)免疫領(lǐng)域創(chuàng)新藥物研發(fā)，包括免疫調(diào)節(jié)機(jī)制、腫瘤免疫、及自身免疫性疾病。鄭彪博士現(xiàn)任邦耀生物首席執(zhí)行官。鄭彪教授學(xué)術(shù)著作豐厚，其中多篇發(fā)表在Nature和Science等世界頂尖雜志上。在馬里蘭大學(xué)、杜克大學(xué)及貝勒醫(yī)學(xué)院工作期間獲得多項(xiàng)重大科研基金，包括美國(guó)NIH科研基金、白血病與淋巴瘤協(xié)會(huì)基金、美國(guó)關(guān)節(jié)炎基金會(huì)、美國(guó)心臟研究協(xié)會(huì)基金、美國(guó)衰老研究聯(lián)盟基金等。在藥物研發(fā)方面，從新藥篩選、靶點(diǎn)研究、疾病模型、臨床前及臨床試驗(yàn)等方面積累了重要的經(jīng)驗(yàn)，對(duì)新藥開(kāi)發(fā)全過(guò)程有深刻的認(rèn)識(shí)。在打造小分子藥，大分子抗體藥，細(xì)胞治療管線(xiàn)均有豐富的經(jīng)驗(yàn)。Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center. He was a tenured professor in the Department of Pathology and Immunology, Baylor College of Medicine. Dr. Zheng worked for GlaxoSmithKline R&D Center as the head of Immunological Discovery Sciences. He was a global vice president of the Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, responsible for the innovative immunological drug pipeline in the region. Dr. Zheng is now the Chief Executive Officer at BRL Medicine.Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 副總裁
所屬公司： 蘇州開(kāi)拓藥業(yè)
個(gè)人簡(jiǎn)介：
許若博士本科就讀于北京大學(xué)化學(xué)系，之后獲美國(guó)哥倫比亞大學(xué)博士學(xué)位。從1998年開(kāi)始，許博士先后在先靈堡雅、默克、API Inc.等美國(guó)大小制藥企業(yè)的工作20多年，在藥物化學(xué)，工藝化學(xué)，原料藥的cGMP制造，CMC文件準(zhǔn)備和提交等領(lǐng)域積累了豐富的經(jīng)驗(yàn)。許博士于2019年4月回國(guó)加入開(kāi)拓藥業(yè)股份有限公司，擔(dān)任化學(xué)副總裁職務(wù)。全面負(fù)責(zé)公司的藥物化學(xué)的研發(fā)和原料藥的生產(chǎn)工作。Dr. Xu received his bachelor's degree in chemistry from Peking University and his Ph.D. from Columbia University. After his academic training, Dr. Xu has worked in pharmaceutical industry for more than 20 years, including Schering-Plough, Merck, API Inc. etc. in the United States. During this time, he accumulated rich experience in medicinal chemistry, process chemistry, cGMP manufacturing of APIs, CMC document preparation and submission, etc. Dr. Xu returned to China in April 2019 and joined Kintor Pharma as Vice President of Chemistry. He is responsible for the medicinal chemistry research and the production of APIs of the company.
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 創(chuàng)始人、董事長(zhǎng)兼總經(jīng)理
所屬公司： 宜明昂科生物醫(yī)藥技術(shù)（上海）股份有限公司
個(gè)人簡(jiǎn)介：
田文志博士，上海市“千人計(jì)劃”專(zhuān)家、浦東新區(qū)“百人計(jì)劃”專(zhuān)家、科技部火炬中心科技創(chuàng)新創(chuàng)業(yè)人才、復(fù)旦大學(xué)藥學(xué)院兼職教授，現(xiàn)任宜明昂科生物醫(yī)藥技術(shù)（上海）股份有限公司董事長(zhǎng)兼總經(jīng)理。于1995年10月至2011年4月先后在瑞典、美國(guó)留學(xué)及工作，主要從事腫瘤免疫學(xué)及抗腫瘤抗體藥物開(kāi)發(fā)研究。累計(jì)發(fā)表學(xué)術(shù)論文30余篇，克隆新基因7個(gè)，參編英文專(zhuān)著一部，申請(qǐng)新藥發(fā)明專(zhuān)利40余項(xiàng)，獲得授權(quán)13項(xiàng)。2011年4月辭職回國(guó)，先后創(chuàng)辦了華博生物醫(yī)藥技術(shù)（上海）有限公司、宜明昂科生物醫(yī)藥技術(shù)（上海）股份有限公司及宜明探科生物醫(yī)藥技術(shù)（上海）有限公司?；貒?guó)12年以來(lái)，已將 8個(gè)新藥項(xiàng)目開(kāi)發(fā)至臨床試驗(yàn)階段，其中7項(xiàng)已開(kāi)展臨床試驗(yàn)。Dr. Wenzhi Tian is the founder and Chairman of IImmuneOnco Biopharmaceuticals (Shanghai) Inc., a clinical stage biotech company headquartered in Shanghai, China, with primary focus on research and development of tumor immunotherapeutic drugs including checkpoint modulators and target-activated NK (TANKTM) products. Prior to ImmuneOnco Biopharma, Dr. Tian worked as Chief Executive Officer at Huabo Biopharm from June of 2011 to April of 2015. During that period, Dr. Tian advanced two large molecule programs to the clinical stage. Prior to moving back to China, Dr. Tian worked as Principal Research Scientist at ImClone Systems from January of 2006 to April of 2011. Dr. Tian graduated from Henan Medical University (Now Zhengzhou University School of Medicine) and did his postdoctoral training at North Shore University Hospital, NYU School of Medicine. He was appointed a Senior Research Associate at Weill Medical College of Cornell University thereafter.
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 執(zhí)行董事、首席執(zhí)行官
所屬公司： 蘇州創(chuàng)勝醫(yī)藥集團(tuán)有限公司
個(gè)人簡(jiǎn)介：
錢(qián)雪明博士是創(chuàng)勝集團(tuán)醫(yī)藥有限公司（下稱(chēng)創(chuàng)勝集團(tuán)）的首席執(zhí)行官。創(chuàng)勝集團(tuán)是一家具備生物藥發(fā)現(xiàn)、研發(fā)、工藝開(kāi)發(fā)和生產(chǎn)全流程整合能力的臨床階段的生物制藥公司。2021年9月29日，創(chuàng)勝集團(tuán)在香港聯(lián)合交易所主板上市，股票代碼：06628。錢(qián)雪明博士畢業(yè)于復(fù)旦大學(xué)生物物理學(xué)系 (1985 – 1990)，并分別在哥倫比亞大學(xué) (Columbia University, 1990 – 1992) 和奧爾巴尼醫(yī)學(xué)中心 (Albany Medical Center, 1995 – 1997) 獲得神經(jīng)學(xué)與生理學(xué)碩士學(xué)位和神經(jīng)學(xué)與藥理學(xué)博士學(xué)位。錢(qián)雪明博士擁有 20 年的生物制藥行業(yè)經(jīng)驗(yàn)。在創(chuàng)立創(chuàng)勝集團(tuán)之前，錢(qián)博士于 2010-2013 年間任盛諾基醫(yī)藥集團(tuán) (Shenogen Pharma Group) 研發(fā)總裁和董事會(huì)成員。1997-2010 間任職于美國(guó)安進(jìn)公司，專(zhuān)注于抗體新藥的開(kāi)發(fā)。錢(qián)博士是十多個(gè)創(chuàng)新藥物專(zhuān)利申請(qǐng)的發(fā)明人，也是國(guó)際抗體協(xié)會(huì)會(huì)員、國(guó)際腎病協(xié)會(huì)會(huì)員、新藥創(chuàng)始人俱樂(lè)部、創(chuàng)新生物社和 BayHelix 百華協(xié)會(huì)會(huì)員，獲得了國(guó)家級(jí)高層次人才、蘇州工業(yè)園區(qū)科技領(lǐng)軍人才和蘇州市姑蘇創(chuàng)新創(chuàng)業(yè)領(lǐng)軍人才等支持。Dr. Xueming Qian is the CEO of Transcenta Holding Limited (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics. Dr. Qian received his B.S. in Biophysics from Fudan University (Shanghai, China, 1985 – 1990), M.A. in Neuroscience/Physiology from Columbia University (New York, USA, 1990 – 1992) and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center (New York, USA, 1995 – 1997).Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder’s Club, Bio-logics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR, ASN and Antibody Society.
微信公眾號(hào)
領(lǐng)導(dǎo)者網(wǎng)絡(luò)APP
Copyright ?2005 - 2017上海士研管理咨詢(xún)有限公司
犀牛云提供企業(yè)云服務(wù)